Comparator sourcing: Leveraging the Bolar exemption to accelerate market access for generic and biosimilar products


This whitepaper provides insight into the changing comparator sourcing landscape, focusing specifically on the instrumental role the Bolar exemption plays in the shift away from dependence on innovators for clinical supplies. Thermo Fisher's Comparator team has the required expertise to leverage the Bolar exemption, providing clients early access to generic / biosimilar drugs.